Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LABNASDAQ:NAUTNASDAQ:QSINYSE:SENS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLABStandard BioTools$1.07+7.2%$1.10$0.92▼$2.60$404.51M1.52.11 million shs674,346 shsNAUTNautilus Biotechnology$0.77+3.8%$0.76$0.66▼$3.09$97.13M1.43119,870 shs114,781 shsQSIQuantum-Si$1.74+8.4%$1.37$0.61▼$5.77$318.37M2.8710.69 million shs3.79 million shsSENSSenseonics$0.54+2.4%$0.61$0.25▼$1.40$353.93M0.976.77 million shs2.41 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLABStandard BioTools-8.33%-6.60%-6.60%-14.66%-61.48%NAUTNautilus Biotechnology-4.50%-7.45%+10.80%-38.33%-71.32%QSIQuantum-Si-8.57%-6.43%+34.45%+24.03%+1.27%SENSSenseonics-1.23%-1.05%-19.95%-18.28%+20.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLABStandard BioTools2.5485 of 5 stars3.33.00.00.01.53.30.6NAUTNautilus Biotechnology2.8951 of 5 stars3.02.00.00.03.64.20.6QSIQuantum-Si2.7567 of 5 stars3.32.00.00.03.72.50.6SENSSenseonics2.2625 of 5 stars3.82.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLABStandard BioTools 2.50Moderate Buy$2.50134.74% UpsideNAUTNautilus Biotechnology 2.00Hold$2.13175.97% UpsideQSIQuantum-Si 2.67Moderate Buy$3.48100.29% UpsideSENSSenseonics 3.50Strong Buy$1.55186.51% UpsideCurrent Analyst Ratings BreakdownLatest NAUT, QSI, LAB, and SENS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025SENSSenseonicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$1.105/19/2025QSIQuantum-SiHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.505/16/2025QSIQuantum-SiAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$2.004/9/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLABStandard BioTools$169.69M2.38N/AN/A($1.85) per share-0.58NAUTNautilus BiotechnologyN/AN/AN/AN/A$2.12 per shareN/AQSIQuantum-Si$3.44M92.47N/AN/A$1.92 per share0.90SENSSenseonics$23.68M14.95N/AN/A$0.07 per share7.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLABStandard BioTools-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)NAUTNautilus Biotechnology-$63.67M-$0.54N/AN/AN/AN/A-28.85%-24.93%7/29/2025 (Estimated)QSIQuantum-Si-$95.96M-$0.68N/AN/AN/A-3,968.84%-36.96%-33.57%8/6/2025 (Estimated)SENSSenseonics-$60.39M-$0.11N/AN/AN/A-362.30%-842.25%-67.99%N/ALatest NAUT, QSI, LAB, and SENS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025QSIQuantum-Si-$0.17-$0.11+$0.06-$0.11$0.96 million$0.84 million4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLABStandard BioToolsN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/AQSIQuantum-SiN/AN/AN/AN/AN/ASENSSenseonicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLABStandard BioToolsN/A3.763.41NAUTNautilus BiotechnologyN/A16.6516.65QSIQuantum-SiN/A13.4213.15SENSSenseonics59.172.472.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLABStandard BioTools53.74%NAUTNautilus Biotechnology50.71%QSIQuantum-Si39.90%SENSSenseonics12.36%Insider OwnershipCompanyInsider OwnershipLABStandard BioTools23.16%NAUTNautilus Biotechnology41.10%QSIQuantum-Si30.04%SENSSenseonics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLABStandard BioTools620379.82 million174.59 millionOptionableNAUTNautilus Biotechnology130126.15 million74.71 millionOptionableQSIQuantum-Si150183.50 million99.84 millionOptionableSENSSenseonics90654.22 million573.90 millionN/ANAUT, QSI, LAB, and SENS HeadlinesRecent News About These CompaniesHC Wainwright Estimates Senseonics FY2025 EarningsJune 5 at 1:21 AM | americanbankingnews.comSenseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with DiabetesJune 4 at 4:05 PM | globenewswire.comAnalysts Offer Predictions for Senseonics FY2025 EarningsJune 4 at 6:06 AM | marketbeat.comSenseonics (NYSE:SENS) Upgraded at HC WainwrightJune 4 at 1:57 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for Senseonics Q2 Earnings?June 3 at 6:02 AM | marketbeat.comSenseonics (NYSE:SENS) Given Buy Rating at HC WainwrightJune 2, 2025 | marketbeat.comSenseonics Holdings, Inc. Secures $57.5 Million in Public Offering and $20.3 Million from Private Placement with Abbott LaboratoriesMay 21, 2025 | quiverquant.comSenseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private PlacementMay 21, 2025 | globenewswire.comRevisiting Senseonics After 4 Years: Still A Big Investment OpportunityMay 21, 2025 | seekingalpha.comJane Street Group LLC Has $3.20 Million Holdings in Senseonics Holdings, Inc. (NYSE:SENS)May 16, 2025 | marketbeat.comSenseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private PlacementMay 15, 2025 | globenewswire.comSenseonics opens $50M public offering, $25M private placement with AbbottMay 15, 2025 | drugdeliverybusiness.comSenseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private PlacementMay 15, 2025 | globenewswire.comSenseonics (NYSE:SENS) Raised to "Sell" at StockNews.comMay 15, 2025 | marketbeat.comSenseonics Holdings, Inc. (AMEX:SENS) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSenseonics Holdings, Inc. Reports First Quarter Financial ResultsMay 9, 2025 | finance.yahoo.comSenseonics posts Q2 sales beat, submits 365-day CGM for CE markMay 9, 2025 | drugdeliverybusiness.comSenseonics targets $34M-$38M revenue in 2025 with Eversense 365 expansionMay 9, 2025 | msn.comSenseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comSenseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSequel Med Tech and Senseonics Partner to Launch twiist™ AID System Compatible with Eversense® 365 CGMApril 30, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesOklo Reaches Critical Mass, Atomic Upside Still AvailableBy Thomas Hughes | May 14, 2025View Oklo Reaches Critical Mass, Atomic Upside Still Available5 Stocks Set to Soar This SummerBy Ryan Hasson | June 2, 2025View 5 Stocks Set to Soar This SummerRocket Lab: Earnings Miss But Neutron Momentum HoldsBy Ryan Hasson | May 12, 2025View Rocket Lab: Earnings Miss But Neutron Momentum HoldsRetail Investors Are Betting Big on Rocket Lab—Should You Too?By Ryan Hasson | May 16, 2025View Retail Investors Are Betting Big on Rocket Lab—Should You Too?Rocket Lab Expands Into Payloads: Should You Be Paying Attention?By Ryan Hasson | June 3, 2025View Rocket Lab Expands Into Payloads: Should You Be Paying Attention?NAUT, QSI, LAB, and SENS Company DescriptionsStandard BioTools NASDAQ:LAB$1.06 +0.07 (+7.15%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Nautilus Biotechnology NASDAQ:NAUT$0.77 +0.03 (+3.77%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Quantum-Si NASDAQ:QSI$1.74 +0.14 (+8.44%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.Senseonics NYSE:SENS$0.54 +0.01 (+2.40%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Market’s Silent Warning: What Bonds and Gold Reveal AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
